Emerging role of liquid biopsy in rat sarcoma virus mutated metastatic colorectal cancer: A case report

Table 3 Rat sarcoma virus mutation status and survival outcomes after second line and third line treatment

Case	2L	PFS 2L (mo)	OS since 2L (mo)	3L	PFS 3L (mo)	OS since 3L (mo)
Case 1	Wild-type	35.86	46.61	Wild-type	6.21	9.96
Case 2	Mutated	3.54	33.57	Neo-RAS	3.86	29.50
Case 3	Mutated	24.39	44.82	Mutated	8.96	12.50
Case 4	Mutated	11.25	28.64	Mutated	3.79	16.39
Case 5	Mutated	9.29	34.61	Mutated	5.18	23.57
Case 6	Mutated	11.25	14.71	Mutated	2.29	2.29
Case 7	Wild-type	14.54	27.64	Wild-type	5.14	11.71
Case 8	Mutated	3.79	4.43	NA	NA	NA
Case 9	Mutated	18.96	32.39	Mutated	3.07	12.43
Case 10	Mutated	4.79	20.93	Mutated	12.93	12.93
Case 11	Wild-type	8.39	8.39	NA	NA	NA

1L: First line; 2L: Second line; 3L: Third line; NA: Not applied; PFS: Progression-free survival; OS: Overall survival; ND: Not determined as patients were kept on second line treatment due to absence of conditions to escalate treatment (Case 8) or to non-progressive disease (Case 11).